

Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation

Latifa Bakiri,^{1*} Rainer Hamacher,^{1*} Osvaldo Graña,² Ana Guío-Carrión,¹ Ramón Campos-Olivas,³ Lola Martínez,⁴ Hans P. Dienes,⁵ Martin K. Thomsen,⁶ Sebastian C. Hasenfuss,¹ and Erwin F. Wagner¹

¹Genes, Development and Disease Group, Cancer Cell Biology Programme, ²Bioinformatics Unit, Structural Biology and Biocomputing Programme, ³Spectroscopy and Nuclear Magnetic Resonance Spectroscopy Unit, Structural Biology and Biocomputing Programme, and ⁴Flow Cytometry Core Unit, Biotechnology Programme, Spanish National Cancer Research Centre (CNIO), E-28029 Madrid, Spain

⁵Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria

⁶Department of Clinical Biomedicine, Aarhus University, DK-8000 Aarhus, Denmark

Human hepatocellular carcinomas (HCCs), which arise on a background of chronic liver damage and inflammation, express c-Fos, a component of the AP-1 transcription factor. Using mouse models, we show that hepatocyte-specific deletion of c-Fos protects against diethylnitrosamine (DEN)-induced HCCs, whereas liver-specific c-Fos expression leads to reversible premalignant hepatocyte transformation and enhanced DEN-carcinogenesis. c-Fos-expressing livers display necrotic foci, immune cell infiltration, and altered hepatocyte morphology. Furthermore, increased proliferation, dedifferentiation, activation of the DNA damage response, and gene signatures of aggressive HCCs are observed. Mechanistically, c-Fos decreases expression and activity of the nuclear receptor LXR α , leading to increased hepatic cholesterol and accumulation of toxic oxysterols and bile acids. The phenotypic consequences of c-Fos expression are partially ameliorated by the anti-inflammatory drug sulindac and largely prevented by statin treatment. An inverse correlation between c-FOS and the LXR α pathway was also observed in human HCC cell lines and datasets. These findings provide a novel link between chronic inflammation and metabolic pathways important in liver cancer.

INTRODUCTION

Primary liver cancer is the fifth and seventh most common cancer in men and women, respectively, and hepatocellular carcinoma (HCC), the most common histological subtype, accounts for 70–85% of cases (Jemal et al., 2011). HCC develops almost exclusively in the context of liver diseases associated with chronic inflammation. For this reason, liver cirrhosis, a consequence of many chronic liver diseases such as viral hepatitis, alcohol-induced hepatitis, or non-alcohol-induced hepatitis, is the main risk factor for HCC (Fattovich et al., 2004). Previous findings using genetically engineered mouse models (GEMMs) indicate that continuous rounds of hepatocyte injury, necrosis, inflammation-induced cell death, and subsequent compensatory proliferation are essential for liver cancer initiation and promotion (Farazi and DePinho, 2006). This is supported by the

fact that during progression of chronic liver disease, HCC risk increases (Fattovich et al., 2004).

Although some improvement in the management of HCC has been achieved in the last 30 years, beneficial treatment is only possible at early stages by local ablative therapies, resection, or transplantation (Villanueva et al., 2013). Long-term prognosis after surgical resection of HCC remains poor, owing to the high rate of metastasis or de novo recurrence. Systemic chemotherapies and targeted therapies have failed in the treatment of HCC (Villanueva et al., 2013). Besides prevention and treatment of the causative liver diseases, early diagnosis, identification of high-risk patients, and prevention of malignant transformation are the most promising approaches. The critical step to identify biomarkers and develop effective preventive therapies is a better understanding of the mechanisms responsible for cancer initiation. The pathways most frequently involved are p53, Wnt/ β -catenin, mTOR, TGF- β , Ras, Rb, HGF/c-Met, and IGF1. Transcription factors such as NF- κ B, c-Myc, and AP-1 play an important role in HCC development (Liu et al., 2002; Wagner and Nebreda, 2009; Jain et al., 2010; He and Karin, 2011; Nault and Zucman-Rossi, 2011).

*L. Bakiri and R. Hamacher contributed equally to this paper.

Correspondence to Erwin F. Wagner: ewagner@cnio.es

R. Hamacher's present address is Dept. of Internal Medicine I/Oncology, Medical University of Vienna, 1090 Vienna, Austria.

S.C. Hasenfuss's present address is Dana-Farber Cancer Institute and Dept. of Cell Biology, Harvard Medical School, Boston, MA 02115.

Abbreviations used: AFP, α -fetoprotein; ALT, alanine aminotransferase; BA, bile acid; DDR, DNA damage response; DEN, diethylnitrosamine; FA, fatty acid; GEMM, genetically engineered mouse model; GS, glutamine synthetase; GSEA, gene set enrichment analysis; HB, hepatoblast; HCC, hepatocellular carcinoma; IHC, immunohistochemical staining; NMR, nuclear magnetic resonance; qRT-PCR, quantitative RT-PCR; RXR, retinoid X receptor; TG, triglyceride.

© 2017 Bakiri et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).



The AP-1 transcription factor is a dimeric complex composed of members of the Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra1, Fra2) families of bZIP proteins. Components of AP-1 including c-Jun and c-Fos are important regulators of tumor development (Eferl and Wagner, 2003). In human HCC, both c-Jun and c-Fos are highly expressed, and genome-wide expression analysis of human HCCs revealed that AP-1 is at the center of an oncogenic signaling network in a subset of HCC with poor prognosis (Yuen et al., 2001; Liu et al., 2002; Lee et al., 2006). Mouse models for liver cancer have further established the importance of AP-1 in liver pathology and HCC (Bakiri and Wagner, 2013). In the diethylnitrosamine (DEN)-induced liver cancer model, mice with liver-specific inactivation of c-Jun have significantly fewer tumors because of p53-dependent apoptosis of tumor cells (Eferl et al., 2003). Consistently, inhibition of JNKs, which activate and stabilize c-Jun, leads to reduced proliferation and increased sensitization toward apoptosis in HCC models in vivo and in vitro (Sakurai et al., 2006; Hui et al., 2007; Wagner and Nebreda, 2009; Seki et al., 2012). c-Jun is specifically required for mouse liver tumorigenesis during cancer initiation, and we have shown that c-Jun promotes preneoplastic cell survival by regulating c-Fos- and SIRT6-dependent expression of survivin (Eferl et al., 2003; Min et al., 2012). The cancer-promoting function of c-Jun was also shown in mouse models for HBV- and HCV-related liver tumorigenesis (Machida et al., 2010; Trierweiler et al., 2016). Finally c-Jun promotes hepatocyte survival in experimental models of hepatitis, ER stress, and activated β -catenin-induced liver damage (Hasselblatt et al., 2007; Fuest et al., 2012; Trierweiler et al., 2012).

The role of c-Fos in HCC development is less well defined. Studies in human HCC cell lines indicate that c-Fos is important for cell migration (Fan et al., 2013), and ectopic expression of c-Fos in immortalized human hepatocytes increased cell proliferation (Güller et al., 2008). We recently documented how distinct AP-1 dimers regulate the expression of PPAR γ in the liver in models of nonalcoholic fatty liver disease (Hasenfuss et al., 2014b), a condition associated with obesity and an established risk factor for HCC (Michelotti et al., 2013). Accumulation of cholesterol, especially free cholesterol and cholesterol derivatives such as oxysterols and bile acids (BAs), promotes hepatotoxicity, oxidative stress, inflammation, and even hepatocyte transformation (Tabas, 2002; Ikonen, 2006; Jusakul et al., 2011; Wang et al., 2013). The nuclear receptor and transcription factor LXR α (*Nr1h3*), which is activated by oxysterols, is essential for cholesterol homeostasis. In the liver, LXR α forms transcriptional heterodimers with retinoid X receptors (RXRs) and mediates cholesterol removal by promoting both cholesterol conversion to BAs and cholesterol excretion to the bile (Calkin and Tontonoz, 2012). As a result, *Lxr α* knockout mice display altered hepatic cholesterol and BA metabolism, with cholesterol accumulation and impaired hepatic function (Peet et al., 1998; Zhang et

al., 2012). The BA receptor FXR (*Nr1h4*) is another important nuclear receptor and RXR dimerization partner essential for lipid and BA homeostasis (Calkin and Tontonoz, 2012). Mice lacking FXR have increased BAs, liver damage, inflammation, and late-onset liver tumors, all prevented by restoring BA homeostasis through BA-sequestering agents or intestinal FXR expression (Kim et al., 2007; Yang et al., 2007; Degirolamo et al., 2015).

In this study, we show that hepatocyte-specific expression of c-Fos leads to reversible premalignant transformation of hepatocytes, with mRNA signatures resembling human HCCs. Importantly, using the DEN experimental HCC model, we demonstrate that c-Fos is essential for hepatocyte transformation and HCC development. Mechanistically, c-Fos negatively regulates LXR α expression, which affects cholesterol and BA homeostasis.

RESULTS

Hepatic c-Fos expression leads to premalignant transformation

To investigate the role of c-Fos expression in liver physiology and carcinogenesis, a hepatocyte-specific doxycycline-switchable mouse model was used. LAP-tTA; *col1a1*:Tet-O -fosFlag double-transgenic mice are referred to as *c-fos^{hep-tetOFF}* mice, and single-transgenic littermates were used as controls throughout the study. Expression of c-Fos was switched on at the age of 3 wk by doxycycline removal. Although endogenous c-Fos is undetectable in control livers, hepatocyte-specific expression of Flag-tagged ectopic c-Fos was observed by immunohistochemical staining (IHC; Fig. 1 A), quantitative RT-PCR (qRT-PCR; Fig. 1 B), and Western blot (Fig. S1 A). No ectopic c-Fos mRNA was detected in any other tissue tested (Fig. S1 B). *c-fos^{hep-tetOFF}* mice had a median survival of 5 mo (Fig. 1 C). Therefore, changes in liver physiology were analyzed at up to 4 mo of c-Fos expression. The first histological observation was single-cell necrosis with surrounding immune cell infiltrates, mainly periportal, at 1 mo (Fig. S1 C). These lesions progressed over time to multiple necrotic foci at 3 and 4 mo (Fig. S1 C). Increased serum alanine aminotransferase (ALT), a marker for liver damage, was observed at 2 mo of c-Fos expression (Fig. 1 D), whereas elevated serum γ -glutamyl transferase and decreased albumin and blood urea nitrogen, all indicative of liver dysfunction, were observed at 4 mo (Fig. S1 D). Macroscopically, progressive hepatosplenomegaly was observed (Fig. 1 E), whereas body weight was not affected (Fig. S1 E). An altered growth pattern of hepatocytes was visible at 4 mo of c-Fos expression, with trabecular proliferation and double as well as poly nuclei (Fig. 1 F). In addition, although the controls showed the expected central vein localization of glutamine synthetase (GS), mutant livers displayed diffuse cytoplasmic staining, indicative of disturbed liver zonation (Fig. 1 F). Moreover, scattered positive staining for the dedifferentiation markers CK19 and Sox9 was apparent (Fig. 1 F) at as early as 2.5 mo of c-Fos expression (Fig. S1 F; see also Fig. 9 E). These results indicate that hepatocyte-specific c-Fos expression leads to




Figure 1. Phenotypic consequences of hepatocyte-specific *c-Fos* expression. Ectopic expression of *c-Fos* was achieved in 3-wk-old mice by doxycycline removal. Mice were analyzed at 1, 2, 3, and 4 mo of *c-Fos* expression. (A) Representative Flag IHC in liver sections from *c-fos*^{hep-tetOFF} and control mice 2 mo after doxycycline removal. (B) qRT-PCR analyses of *c-fos* in different tissues. Bar graphs represent mean \pm SD; $n = 2/3$; mean expression in controls set to 1; ***, $P \leq 0.001$ by Student's *t* test. (C) Kaplan-Meier curve ($n = 5$ /cohort); 5 mo = median survival in mutants. *, $P \leq 0.05$. (D and E) Serum ALT (D; $n = 4; 12; 3; 9/3; 11; 3; 6$) and liver/body and spleen/body weight ratio (E; $n = 4; 5; 3; 10/3; 5; 3; 7$) upon *c-Fos* expression. Plots represent mean \pm SD. ***, $P \leq 0.001$ by two-way ANOVA. (F) Representative liver pictures, H&E, and IHC for GS, CK19, and Sox9 in *c-fos*^{hep-tetOFF} and controls at 4 mo. (G) Normalized enrichment scores at 4 mo ectopic *c-Fos* expression relative to controls (RNA-seq, $n = 3$ /cohort) compared with human HCC molecular classes and relevant gene signatures by GSEA. False discovery rate (FDR) q -values are indicated on the right side. n.a., not applicable, as the published gene signature was unidirectional (only enriched genes). Hatched bars highlight inverse correlations computed with up-regulated (red) or down-regulated (green) gene sets. (H) Representative IHC for AFP and β -catenin in *c-fos*^{hep-tetOFF} and controls at 4 mo. (A, F, and H) Bars: (F, left) 1 cm; (A, F [right], and H) 100 μ m.

altered hepatocyte morphology, necrosis, and a dedifferentiated phenotype indicative of premalignant transformation.

Fos-expressing mouse livers exhibit molecular characteristics of human HCCs

Genome-wide transcription profiling using RNA-seq of liver mRNA at 4 mo of *c-Fos* expression was compared by gene set enrichment analysis (GSEA) with the well-established molecular classifications of human HCC (reviewed in Hoshida et al., 2010; van Malenstein et al., 2011; Pinyol et al., 2014). Notably, a significant positive correlation was observed with the hepatoblast (HB) subtype of human HCC with poor prognosis (Fig. 1 G), in which *c-Fos/AP-1* was previously shown to be up-regulated and located in the center of an oncogenic signaling network (Lee et al., 2006). *c-Fos*-expressing gene expression profiles also significantly correlated with published HCC gene signatures, in particular the subtypes G3 (Boyault et al., 2007), S1 (Hoshida et al., 2009), the proliferative class (Chiang et al., 2008), and pediatric hepatoblastoma (Cairo et al., 2008; Fig. 1 G). These gene signatures are all characteristic of dedifferentiation, fetal liver-like gene expression, high proliferation, and aggressiveness (Hoshida et al., 2010; van Malenstein et al., 2011; Pinyol et al., 2014). We also observed a significantly positive correlation, with a 590-gene signature differentially expressed across mouse primary hepatic progenitor cells, HBs, and transformed adult hepatocytes (Holczbauer et al., 2013), whereas a significant inverse correlation was computed with signatures derived from healthy livers (Hsiao et al., 2001) or the well-differentiated and less aggressive S3 HCC subclass (Hoshida et al., 2009). A large fraction of these correlations could already be computed in RNA-seq profiles of livers expressing *c-Fos* at 2 mo (Fig. S1 G). These results imply that *c-Fos* expression leads to molecular characteristics of hepatocyte dedifferentiation and premalignant transformation. Consistent with dedifferentiation and premalignant transformation, α -fetoprotein (AFP) positivity and nuclear β -catenin were also observed (Fig. 1 H). Because *c-Fos* mutant mice showed dramatically reduced survival as a result of hepatic dysfunction, we speculate that *c-Fos*-expressing mice die before these premalignant cells progress to HCCs.

Liver carcinogenesis is enhanced by *c-Fos* expression

To circumvent the lethality induced by sustained *c-Fos* expression, the DEN-induced experimental carcinogenesis paradigm was applied to adult mice, with *c-Fos* expression restricted to tumor initiation (Fig. 2 A). In this setting, control mice very rarely developed HCCs (Bakiri and Wagner, 2013). However, when ectopic *c-Fos* expression was induced for a short period during DEN-induced tumor initiation, tumor development at 7 mo was significantly increased (Fig. 2 A). qRT-PCR analyses revealed increased *c-Fos* expression in tumor-bearing livers, whereas ectopic *c-Fos* was not expressed (Fig. S2 A). These data strongly imply a promoting function of

c-Fos operating during the early events of malignant hepatocyte transformation and HCC development.

DEN-induced HCC formation requires *c-Fos* expression

We next applied the DEN-induced mouse liver cancer model to mice with hepatocyte-specific knockout of *c-Fos* (*c-fos^{Alf}*). Mice with conditional alleles (*c-fos^{Alf}*) combined with the *Alfp-Cre* transgene were used to delete *c-fos* specifically in hepatocytes (Kellendonk et al., 2000; Fleischmann et al., 2003). DEN was injected in 2-wk-old pups to allow efficient tumor formation. Whereas all control mice developed multiple HCCs 8 mo later, *c-fos^{Alf}* mice hardly developed any visible tumor (Fig. 2 B and Fig. S2 B). Histological analyses documented a significantly reduced number and size of foci in these mutants, which mainly displayed nodular proliferation and almost no HCC. PCR analyses of genomic DNA from liver and tumor tissue confirmed deletion of *c-fos* in *c-fos^{Alf}* mice (Fig. S2 C). Moreover, DEN-induced DNA adducts were increased in *c-fos^{Alf}* mice (Fig. S2 D), indicating that decreased tumor load in *c-Fos* mutants is not caused by decreased carcinogenic DEN metabolites.

Genome-wide transcription profiling using RNA-seq was performed using liver mRNA from *c-fos^{Alf}* mice 48 h after DEN injection. Strikingly, several of the gene sets that correlated with *Fos*-overexpressing livers were also found enriched in the dataset from DEN-injected *c-fos^{Alf}* mice but in the opposite direction. Most notably, whereas the S3-HCC subclass and healthy liver-specific genes were positively correlated with the *c-fos^{Alf}* expression dataset, the HCC-HB subtype, the S1 and proliferative HCC subclasses, and the gene set characteristic of dedifferentiated/transformed hepatocytes were negatively correlated (Fig. 2 C). These data further confirm the association between *c-Fos* expression and malignant hepatocyte transformation during HCC and establish that *c-Fos* is not only sufficient to induce malignant transformation of hepatocytes, but is also required for HCC development in vivo.

Liver inflammation and genotoxic stress induced by *c-Fos*

The *c-Fos*-induced hepatomegaly and premalignant transformation was accompanied by an increase in the number of Ki67-positive nuclei indicative of proliferation (Fig. 3, A and B). S139 phosphorylation of histone H2AX (γ H2AX), a surrogate marker of DNA damage (Kinner et al., 2008), and increased p53- and p21-positive nuclei (Fig. 3, A and B) were also observed, indicating that the DNA damage response (DDR) was activated. Although necrosis was apparent, no obvious hepatocyte apoptosis was detected by cleaved caspase 3 IHC (not depicted). Significantly more immune cells were detected in the liver, in particular myeloperoxidase-positive granulocytes (Fig. 3, C and D). Flow cytometry analyses confirmed the accumulation of CD45-positive cells in the liver (Fig. S2 E) and the specific increase in Gr1⁺ cells at 2 mo, whereas NK and B cells were reduced (Fig. 3 E). Increased circulating leukocytes and granulocytes were also observed in




Figure 2. c-Fos expression promotes and is essential for HCC development. (A) 5-wk-old *c-fos*^{hep-tetOFF} and controls were injected with 100 mg/kg DEN, while c-Fos expression was maintained from 3 to 9 wk. Representative liver pictures and histology 7 mo after DEN. (Right) Macroscopic and histological tumor quantification at 7 mo ($n = 6/5$). (B) 15-d-old *c-fos*^{Δli} and *c-fos*^{fl/fl} littermates were injected with 25 mg/kg DEN. Representative liver pictures and H&E 8 mo later. (Right) Histological tumor quantification in *c-fos*^{Δli} and controls 8 mo after DEN ($n = 14/10$). (A and B) Bars: (top) 1 cm; (bottom) 100 μ m. T, tumor. Bar graphs represent mean \pm SD; *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$ by Student's *t* test. (C) Normalized enrichment scores 48 h after DEN injection in 8-wk-old *c-fos*^{Δli} mice relative to controls (RNA-seq, $n = 3$ /cohort) compared with human HCC molecular classes and relevant gene signatures by GSEA. False discovery rate (FDR) q -values are indicated on the right side. n.a., not applicable, as the published gene signature was unidirectional (with only enriched genes). n.s., not significant, as only one out of the two signatures published for the gene set was enriched in the GSEA. Hatched bars highlight inverse correlations computed with up-regulated (red) or down-regulated (green) gene sets. Note that the enrichment scores in *c-fos*^{Δli} livers are inverse orientation, compared with the analysis of *c-fos*^{hep-tetOFF} livers presented in Fig. 1 G and Fig. S1 G.




Figure 3. c-Fos-dependent proliferation, DDR, and inflammation. (A) Representative IHC pictures for Ki67, S139 phosphorylation of histone H2AX (γ H2AX), p53, and p21 in *c-fos*^{hep-tetOFF} and controls at 4 mo. (B) Quantification of Ki67- and γ H2AX-positive hepatocytes at different time points ($n = 4; 5; 3; 7/3; 5; 3; 6$ and $4; 4; 2; 4/5; 5; 3; 7$) and of p21- and p53-positive hepatocytes at 4 mo ($n = 4/5$). (C) Representative IHC pictures for CD45 and myeloperoxidase (MPO) at 4 mo. (D) Quantification of CD45-positive cells in liver sections ($n = 3; 5; 4/3; 5; 4$). (E) Immune cell subtypes in the liver at 2 mo (flow cytometry, $n = 6/8$). (F) Blood cell count of white blood cells (WBC), lymphocytes (LYM), and granulocytes (GRA) at the indicated time points of ectopic *c-Fos* expression ($n = 4; 7; 6; 8/3; 6; 7; 6$). Bars, 100 μ m. Bar graphs and plots represent mean \pm SD; *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$; ns, not significant by Student's *t* test or two-way ANOVA.

the blood at later time points (Fig. 3 F), consistent with hepatic immune cell infiltration and increased spleen size. Several pro-inflammatory and pro-oncogenic pathways are activated in the livers of *c-fos*^{hep-tetOFF} mice, as indicated by increased phosphorylation of Stat3, Jnk1/2, and Akt (Fig. S2 F), likely as a response to increased inflammation and genotoxic stress. These data imply that c-Fos-induced liver inflammation, hepatocyte proliferation, and DDR activation are early events.

We next examined the early events occurring after DEN injection in the livers of c-Fos gain- and loss-of-function GEMMs. 8-wk-old *c-fos*^{hep-tetOFF} mice allowed to express c-Fos for 5 wk were injected with DEN and analyzed 48 h later. Similar to our observations when c-Fos was expressed for 1 mo in the absence of DEN (Figs. 1 and 3), serum ALT and hepatocyte apoptosis were not changed (Fig. S3 A). Short-term ectopic c-Fos expression combined with DEN appeared to have little effect on immune cell infiltration or proliferation (Fig. 4, A and B). However, despite comparable γ H2AX counts, p53- and p21-positive nuclei were increased (Fig. 4, C and D), indicating that increased DDR likely contributes to tumorigenesis when c-Fos expression is combined with DEN.

Deletion of c-Fos in hepatocytes did not affect serum ALT or cell death under basal conditions or 48 h after DEN injection (Fig. S3 B), and c-Fos also had little impact on immune cell infiltration after DEN injection (Fig. 4 E). However, *c-fos*^{Ali} mice showed increased γ H2AX-positive nuclei and reduced compensatory proliferation after DEN-induced liver damage (Fig. 4, F and G), possibly accounting for decreased tumor load.

We next investigated whether c-Fos is necessary to maintain the premalignant phenotype and took advantage of the tetracycline control of c-Fos expression in *c-fos*^{hep-tetOFF} mice. c-Fos expression was induced for 4 mo, and the mice were subsequently put back on doxycycline to repress c-Fos expression. 2 mo later, c-Fos expression in *c-fos*^{hep-tetOFF} reverted mice was comparable with that of controls, and ectopic c-Fos was undetectable (Fig. S3 C). Furthermore, no hepatosplenomegaly was observed (Fig. S3 D), and serum ALT and blood cell counts were comparable with those of control mice (Fig. S3, E and F). Histological analyses confirmed normal liver morphology with no Ki67-, CK19-, or γ H2AX-positive hepatocytes and no immune cell infiltration (Fig. 4 H and Fig. S3 G). The *c-fos*^{hep-tetOFF} reverted mice were viable and appeared healthy more than 6 mo after turning off c-Fos expression (not depicted). These results demonstrate that liver damage, inflammation, hepatocyte proliferation, and preneoplastic transformation induced by c-Fos expression are reversible and that c-Fos is essential to maintain the premalignant phenotype.

Hepatic metabolic pathways are affected by c-Fos

We next analyzed the three gene expression profiles obtained by RNA-seq using Ingenuity Pathway Analysis. The 10 top regulated pathways common to all datasets revealed a potential Fos-dependent regulation of metabolic pathways,

particularly the ones connected to cholesterol and fatty acid (FA) metabolism. In particular, the LXR/RXR pathway was down-regulated upon c-Fos expression and up-regulated in *c-fos*-deficient mice (Fig. 5 A). GSEA confirmed that genes in cholesterol and FA biosynthesis were repressed in *c-fos*^{hep-tetOFF} mice and enriched in *c-fos*-deficient mice (Fig. 5 B).

Liver metabolites were next analyzed by nuclear magnetic resonance (NMR) spectroscopy. Increased cholesterol species were observed in the livers of *c-fos*^{hep-tetOFF} mice relative to controls, whereas triglycerides (TGs) and FAs were not affected (Fig. 5 C). Hepatic cholesterol accumulation in *c-fos*^{hep-tetOFF} mice was confirmed by a colorimetric assay, which also indicated that the ratio between cholesterol species was unaffected (Fig. 5 D). On the other hand, serum cholesterol was reduced at 4 mo of hepatic c-Fos expression (Fig. S4 A), with a decreased esterified/free cholesterol ratio (Fig. S4 B), and restored in the *c-fos*^{hep-tetOFF} reverted mice (Fig. S4 C). These results demonstrate that cholesterol accumulation in hepatocytes is a phenotypic consequence of increased c-Fos expression.

LXR α -mediated cholesterol accumulation in Fos-expressing livers

The nuclear receptor LXR α (*Nr1h3*) is a major regulator of cholesterol homeostasis responsible for cholesterol elimination from the cell (Calkin and Tontonoz, 2012). qRT-PCR analyses of genes involved in cholesterol homeostasis and FA and TG synthesis, including bona fide LXR α target genes, were performed. Several LXR α target genes such as *abcg5*, *abcg8*, *fasn*, and *acaca* were significantly down-regulated at 1 mo of c-Fos expression (Fig. 6, A and B). Consistent with the Ingenuity analysis, reduced expression of genes involved in cholesterol synthesis was observed at 2 mo (Fig. 6 C), indicating compensatory down-regulation. No significant changes in expression of LXR α target genes could be observed in *c-fos*-deficient or reverted livers (Fig. S4, D and E).

Oxysterols, which are cholesterol metabolites and natural ligands for LXR α , were next analyzed by mass spectrometry. Total and free oxysterols were significantly increased in livers of *c-fos*^{hep-tetOFF} mice (Fig. 6 D, and Fig. S4 F, and Table S1), consistent with increased cholesterol and decreased expression of the *Abcg5/Abcg8* transporter, which promotes cholesterol excretion from hepatocytes into bile, and further indicating that reduced activity of LXR α is not caused by lack of ligands. *Cyp7a1*, the rate-limiting enzyme for primary BA synthesis, is also modulated by LXR α in mice and was decreased at 2 mo of c-Fos expression (Fig. 6 A and Fig. S4 G). However, hepatotoxic primary BAs (CA, CDCA, and α MCA) were significantly increased in the liver (Fig. 6 E and Table S1), which could be explained by the overall increase in cholesterol. On the other hand, hepatoprotective taurine conjugates (TDCA and TUDCA) were reduced (Fig. 6 E), consistent with reduced mRNA expression of *Baat* and *Sc127a5*, two enzymes responsible for BA-amino acid conjugation (Fig. S4 G). BAs were also increased in serum of





Figure 4. **c-Fos-dependent early carcinogenic events and phenotype reversibility.** (A–D) Quantification of CD45-positive cells (A; $n = 5/5$) and Ki67-positive (B; $n = 5/5$), γ H2AX-positive (C; $n = 4/5$), and p53-positive ($n = 4/5$) and p21-positive (D; $n = 4/5$) hepatocytes in liver sections from 8-wk-old *c-fos*^{hep-tetOFF} and control mice 48 h after DEN. (E–G) Quantification of CD45-positive (E; $n = 8; 6/8; 5$) and BrdU-positive (F; $n = 4; 7/3; 6$) cells around the central vein (CV) and γ H2AX-positive hepatocytes (G; $n = 4/5$) in liver sections from 8-wk-old *c-fos*^{Δli} and control mice untreated (0) and 48 h after DEN. (A–G) Plots represent mean \pm SD; *, $P \leq 0.05$; ***, $P \leq 0.001$ by Student's *t* test. (H) Ectopic expression of c-Fos was allowed during 4 mo and then stopped by administration of doxycycline. Representative liver histology (H&E) and IHC (Ki67, CD45, CK19, and γ H2AX) from *c-fos*^{hep-tetOFF} and controls 2 mo after switching off c-Fos expression. Bars, 100 μ m.



c-fos^{hep-tetOFF} mice (Fig. 6 F) reflecting both the hepatic increase in toxic BA species and liver damage. These results indicate that c-Fos expression affects LXR α -mediated control of cholesterol homeostasis, leading to compensatory reduced expression of genes involved in cholesterol synthesis and the accumulation of potentially toxic cholesterol species and derivatives in the liver.

Inhibition of LXR α expression by c-Fos

A notable down-regulation of hepatic LXR α mRNA was found in *c-fos*^{hep-tetOFF} mice (Fig. 7, A and B). This effect is likely cell autonomous to hepatocytes, as it was also observed in primary hepatocytes isolated from Fos^{tetON} mice and induced to express c-Fos by addition of doxycycline to the culture medium (Fig. 7 C). Consistently, reduced mRNA of some LXR α target genes was also observed (Fig. 7 C). Although the mRNA of PPAR γ , a direct c-Fos target gene (Hasenfuss et al., 2014b), was up-regulated in primary hepatocytes (Fig. 7 C) as well as in *c-fos*-expressing livers (Fig. 7 A and Fig. S4 H), mRNA expression of the BA receptor FXR (encoded by Nr1h4) was also found to be increased (Fig. 7 A and Fig. S4 H), indicating possible regulation by c-Fos or, as previously reported (Zhang et al., 2004), by PPAR γ . No consistent changes in mRNA expression of other nuclear receptors, such as PPAR α / δ or RXRs, were observed in RNA-seq or qRT-PCR analyses (Fig. 7 A and Fig. S4 H).

Decreased Lxr α protein was already detectable at 1 mo in hepatic protein extracts from *c-fos*^{hep-tetOFF} mice (Fig. 7 D), consistent with reduced LXR α target genes and decreased LXR α pathway activity. LXR α protein expression was comparable to controls in *c-fos*-deficient livers under basal conditions. However, LXR α protein was significantly up-regulated in *c-fos*-deficient livers 2 wk after DEN-induced carcinogenesis (Fig. 7 E).

The Srebf1/Srebf2 transcription factors are also involved in cholesterol homeostasis and FA metabolism. GSEA revealed down-regulation of Srebf target genes (Horton et al., 2003) in *c-fos*-expressing livers, whereas these genes were induced in DEN-treated *c-fos*-deficient livers (Fig. S4 I). Although Srebf1 mRNA was reduced in *c-fos*-expressing livers at the 2-mo time point (Fig. 6 B), consistent with its reported transcriptional modulation by LXR α , increased cleaved (active) Srebf1 protein was detected, in particular at the late time point (Fig. S4 J). In the same samples, cleaved (active) Srebf2 protein was decreased, whereas Srebf2 mRNA appeared unchanged (Fig. S4, J and K). These results suggest that c-Fos-dependent alterations in LXR/RXR activity caused by decreased expression of LXR α are likely responsible for the observed metabolic changes.

Inhibiting inflammation by sulindac treatment

The contribution of inflammation to the complex phenotypic changes induced by hepatic c-Fos expression was explored next. Control and *c-fos*^{hep-tetOFF} mice were treated with the COX1/2 inhibitor sulindac for 2 mo starting at 2 mo of

c-Fos expression (Fig. 8 A). Sulindac had no effect on hepatic expression of total or ectopic c-Fos (Fig. S5 A). Increased liver size, serum ALT, and serum BA were still apparent in sulindac-treated mutant mice (Fig. 8, B and C). However, liver histology revealed normalized numbers of Ki67, reduced CD45-positive cells, and numerous hepatocytes positive for the dedifferentiation markers CK19 and Sox9 and γ H2AX (Fig. 8, E and F). In addition, whereas serum cholesterol appeared to be normalized (Fig. S5 B), liver cholesterol species were still elevated in sulindac-treated mutant mice (Fig. 8 G). Consistently, mRNA expression of LXR α and most LXR α target genes was significantly reduced (Fig. 8 H).

These results suggest that hepatic inflammation contributes to sustaining hepatocyte proliferation upon c-Fos expression but has little contribution to c-Fos-dependent alterations in LXR/RXR activity, hepatic cholesterol accumulation, activation of DDR, and hepatocyte preneoplastic transformation.

Statin treatment partially reverses the c-Fos-dependent hepatic phenotype

The contribution of cholesterol and BA metabolism to the phenotype was next assessed using an inhibitor of the HMG-CoA reductase (HMGCR) atorvastatin (in short, statin). HMGCR catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. Although cholesterol synthesis pathway activity was overall decreased (Figs. 5 A and 6 C), *Hmgcr* was up-regulated in the livers of *c-fos*^{hep-tetOFF} mice at 2 mo (Fig. S5 C), indicating that statin treatment might be effective. Additionally, besides decreasing circulating cholesterol and increasing intestinal excretion of cholesterol and BA (Parker et al., 2013), atorvastatin is reported to increase hepatic mRNA expression of *Cyp7a1*, *Abcg5*, and *Abcg8* in wild-type mice (Fu et al., 2014). *c-fos*^{hep-tetOFF} mice were subjected to statin treatment for 2 wk, starting at 2 mo of c-Fos expression (Fig. S5 D). A smaller cohort of littermate controls was processed in parallel. No changes in total or ectopic c-Fos expression were observed in statin-treated mice (Fig. S5 E). Although statin treatment moderately affected serum ALT (Fig. 9 A), serum BAs were decreased to control levels in treated mutants (Fig. 9 B). Statin decreased circulating cholesterol and low-density lipoprotein (LDL) cholesterol in controls, as expected (Lawman et al., 2004; Parker et al., 2013), but did not further decrease these parameters in mutant mice (Fig. 9 C and Fig. S5 F). Consistent with a previous study (Parker et al., 2013), statin did not affect total hepatic cholesterol (Fig. 9 C). Importantly, statin increased hepatic mRNA expression of *Abcg5*, *Abcg8*, *Cyp7a1*, and *Hmgcs1* in all treated groups, with the levels of *Abcg5* and *Abcg8* in statin-treated mutants reaching those of untreated controls (Fig. 9 D). Although hepatic Ki67- and CD45-positive cells were slightly diminished, no AFP-positive hepatocytes could be detected (Fig. S5 G), and significantly fewer hepatocytes expressed CK19 and Sox9 by qRT-PCR (Fig. 9 D) and IHC (Fig. 9 E) upon statin treatment. Furthermore, γ H2AX-, p53-, and p21-positive hepatocytes




Figure 6. **Metabolic gene expression and cholesterol derivatives in *c-fos*^{hep-tetOFF} mice.** (A–C) qRT-PCR analyses of genes involved in cholesterol homeostasis (A), FA and TG (B), and cholesterol (C) synthesis in liver of *c-fos*^{hep-tetOFF} and controls at 1 and 2 mo of *c-Fos* expression ($n = 3/5$); mean expression in each control group set to 1. (D and E) Free and total oxysterol (D) and BA (E) species in liver extracts from *c-fos*^{hep-tetOFF} at 4 mo of *c-Fos* expression ($n = 5$ /cohort) determined and quantified by MS. Names of oxysterol and BA species are listed in Table S1. (F) Serum BAs (colorimetry) at the indicated time points of *c-Fos* expression ($n = 9; 3; 12/11; 4; 8$). Plots and bar graphs represent mean \pm SD; *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$ by two-way ANOVA or Student's *t* test.




Figure 7. **Regulation of LXRα expression by c-Fos.** (A) Relative expression of the indicated nuclear receptors, including Nr1h3 encoding for LXRα, by RNA-seq in *c-fos*^{hep-tetOFF} mice at 2 and 4 mo of ectopic c-Fos expression; (*n* = 2; 3/cohort) and in *c-fos*^{Δli} mice 48 h after DEN (*n* = 3/cohort). Bar graphs represent mean fold changes (log₂); # indicates significance after multiple testing corrections. (B) qRT-PCR analyses of *Lxrα* in total liver tissue of *c-fos*^{hep-tetOFF} and control mice at 1, 2, and 4 mo of c-Fos expression. Mean expression in controls set to 1; *n* = 5; 5; 7/5; 5; 7. (C) qRT-PCR analyses of Fos^{tetON} primary hepatocytes (*n* = 4 mice/culture) induced to express c-Fos in vitro during 48 h. Expression in untreated cells set to 1. (D) Immunoblot analyses of total liver lysates from *c-fos*^{hep-tetOFF} at 1 wk and 1, 2, and 4 mo of c-Fos expression. (Right) Immunoblot quantification normalized to vinculin (*n* = 3; 7; 6; 12/2; 8; 9; 12). (E) LXRα immunoblot of liver lysates from *c-fos*^{Δli} untreated (0 h), 48 h, and 2 wk after DEN injection. (Right) Immunoblot quantification normalized to vinculin (*n* = 2; 9; 5/2; 9; 5). Molecular mass is indicated in kilodaltons. (B-E) Bar graphs represent mean ± SD; *, *P* ≤ 0.05; ***, *P* ≤ 0.001 by Student's *t* test.

cytes were notably decreased in statin-treated *c-fos*^{hep-tetOFF} mice (Fig. 9, E and F; and Fig. S5 G).

These results suggest that the *c-Fos*-dependent DDR activation and preneoplastic transformation of hepatocytes are likely caused by decreased expression of the *Abcg5/Abcg8* sterol transporter and *LXR/RXR* target genes and by the subsequent alterations in cholesterol and BA metabolism.

Pathway conservation in human liver cells

Using the Cancer Cell Line Encyclopedia of the Broad Institute, an inverse correlation of *c-FOS* expression with *LXR α* and its target genes was observed in human HCC cell lines (Fig. 10 A) and confirmed by qPCR analyses comparing the *c-Fos* low-expressing HepG2 to the high-expressing Huh7 and SNU354 HCC cell lines (Fig. 10 B). A significant negative correlation between *c-FOS* and *LXR α* target genes (*FASN*, *ABCG8*, *ABCG5*) was also computed in the gene expression dataset of the HB subtype of human HCC (Fig. 10 C). These correlations suggest that the conclusions drawn from analyzing GEMMs are likely relevant for human HCCs. We next attempted to define the connection between *c-FOS* and *LXR α* using human cells. *PPAR γ* , a direct *c-Fos/AP-1* target gene, is up-regulated in mouse hepatocytes expressing *c-Fos* (Hasenfuss et al., 2014b; Fig. 7 C and Fig. S4 H). In rat primary hepatocytes and mouse livers, activation of *PPAR α/γ* was reported to decrease *LXR α /RXR* activity (Yoshikawa et al., 2003). This was also observed in primary human hepatocytes and the HepaRG hepatoma cell line (Rogue et al., 2011), in which treatment with *PPAR γ* agonists notably decreased the expression of *ABCG5*, *ABCG8*, and *CYP7A1* (Fig. 10 D). Decreased mRNA of *ABCG5*, *ABCG8*, and *CYP7A1*, and to a lesser extent, *LXR α* and *FASN*, was also observed in HepG2 cells treated with the *PPAR γ* agonist pioglitazone (Fig. 10 E), whereas *c-FOS*, *PPAR γ* , and *FXR* were unaffected and the *PPAR γ* target gene *FABP1* was up-regulated (Fig. S5 H). Increased *PPAR γ* in *c-Fos*-expressing hepatocytes is therefore likely to be responsible for decreased *LXR α* expression and activity. Whether decreased *LXR α* expression and activity in liver cells occurs through direct binding of *PPAR γ* to the *LXR α* promoter, as shown in human macrophages (Chinetti et al., 2001; Laffitte et al., 2001), or rather, as proposed by Yoshikawa et al. (2003), through competitive reduction of *LXR/RXR* dimers, remains to be addressed.

DISCUSSION

GEMMs are essential for advancing the molecular understanding of the basic mechanisms of liver diseases (Bakiri and Wagner, 2013). Here we show for the first time that hepatocyte-specific expression of *c-Fos* leads to liver inflammation, hepatocyte proliferation, DDR activation, and premalignant transformation, which depends on sustained *c-Fos* expression. When *c-Fos* expression is experimentally switched off, a complete regression of the phenotype is observed. However, when combined with a potent mutagen, such as DEN, to provide a second pro-oncogenic signal, *c-Fos* promotes HCC

development. Importantly, carcinogenesis experiments using loss-of-function GEMMs show that *c-Fos* is not just sufficient, but essential for HCC development.

Mechanistically, hepatocyte-specific *c-Fos* expression leads to hepatic cholesterol accumulation, likely as a result of reduced expression and activity of the nuclear receptor *LXR α* , which is essential for cholesterol homeostasis (Peet et al., 1998; Calkin and Tontonoz, 2012; Zhang et al., 2012). Accumulation of cholesterol and toxic cholesterol derivatives (such as oxysterols and primary BAs), DDR activation, and subsequent inflammation and hepatocyte proliferation are the initiators of the premalignant phenotype in *c-fos*^{hep-tetOFF} mice (Fig. 10 F).

A significant correlation with several human HCC signatures characteristic of poorly differentiated, aggressive tumors, such as the S1 and G3 and the proliferative classes (Boyault et al., 2007; Chiang et al., 2008; Hoshida et al., 2009, 2010; van Malenstein et al., 2011; Pinyol et al., 2014), was identified using RNA-seq profiles of *c-Fos*-expressing murine livers. The correlation with the specific HB subtype of human HCCs with poor prognosis identified by Lee et al. (2006) is particularly compelling. Network-based analyses revealed high *Fos/AP-1* activity in this subtype, and *AP-1* was proposed as the main oncogenic driver (Lee et al., 2006). Our data experimentally support this hypothesis, as we observed not only a strong positive correlation with the HB subtype in livers from the *c-fos*^{hep-tetOFF} mice, but also a significant inverse correlation in the tumor-resistant, hepatocyte-specific *c-Fos* knockout livers. This inverse correlation pattern of *Fos*-expressing and *Fos*-deficient livers was also observed with the HCC classification signatures and signatures characteristic of dedifferentiated/transformed or healthy livers (Hsiao et al., 2001; Cairo et al., 2008; Holczbauer et al., 2013). Besides the molecular signatures, necrosis, inflammation, proliferation, and dedifferentiation were histologically observed, all consistent with premalignant transformation. *c-fos*^{hep-tetOFF} mice did not develop HCC, most likely because of their reduced life-span. However, when *c-Fos* expression was restricted to the initiation stage of DEN-induced carcinogenesis, liver tumors efficiently developed, indicating that *c-Fos* is a potent inducer of hepatocyte transformation.

We previously reported that *c-Jun* promotes HCC by repressing *c-Fos* expression in hepatocytes, thus modulating a *SIRT6/Survivin* axis and initiating cancer cell survival (Min et al., 2012). In the current study, ectopic expression of *c-Fos* in *c-Jun*-proficient livers leads to hepatocyte proliferation, DDR activation, and premalignant transformation, whereas *c-Fos* inactivation conversely decreases DEN-induced hepatocyte proliferation and carcinogenesis. These new findings thus indicate that the functions and pathways controlled by *c-Fos* in liver carcinogenesis are multiple and stage, context, and *c-Jun/AP-1* dependent.

c-Fos affects the *LXR/RXR* pathway controlling hepatic cholesterol. 1 mo of *c-Fos* expression already leads to reduced pathway activity, with a subsequent increase in total




Figure 8. **Phenotypic consequences of inhibiting inflammation in *c-fos^{hep-tetOFF}* mice.** (A) Ectopic expression of c-Fos was allowed during 2 mo and then combined with sulindac for an additional 2 mo. (B–D) Liver/body weight (B), serum ALT (C), and serum BAs (D) in sulindac-treated *c-fos^{hep-tetOFF}* and controls ($n = 6/6$). (E) Representative IHC for Ki67, CD45, γ H2AX, CK19, and Sox9 in sulindac-treated *c-fos^{hep-tetOFF}* and controls. Bars, 100 μ m. (F) Quantification of CD45-positive cells and Ki67- and γ H2AX-positive hepatocytes in liver sections of sulindac-treated *c-fos^{hep-tetOFF}* and controls ($n = 6/6$). (G) Liver cholesterol species in sulindac-treated *c-fos^{hep-tetOFF}* and controls ($n = 6/6$). (H) qRT-PCR analyses in total liver tissue from sulindac-treated *c-fos^{hep-tetOFF}* and controls ($n = 6/6$, mean expression in controls set to 1). Bar graphs represent mean \pm SD; *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.01$ by Student's *t* test.




Figure 9. **Phenotypic consequences of statin treatment in *c-fos*^{hep-tetOFF} mice.** (A–C) Serum ALT (A), serum BAs (B), and serum and liver total cholesterol (C) in untreated and statin-treated *c-fos*^{hep-tetOFF} and controls ($n = 2; 2/4; 6$). (D) qRT-PCR analyses in total liver tissue from untreated and statin-treated *c-fos*^{hep-tetOFF} and controls ($n = 2; 2/3; 5$, mean expression in untreated controls set to 1). (E) Representative IHC for Ki67, CD45, γH2AX, p21, CK19, and Sox9 in untreated and statin-treated *c-fos*^{hep-tetOFF} and controls. Bars, 100 μm. (F) Quantification of CD45-positive cells and Ki67-, γH2AX-, p53-, and p21-positive hepatocytes in liver sections of untreated and statin-treated *c-fos*^{hep-tetOFF} and controls ($n = 2; 2/4; 6$). Bar graphs represent mean ± SD. *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$ by Student's *t* test.




Figure 10. **Liver carcinogenesis by c-Fos in human HCC and GEMMs.** (A) Correlation analyses of c-FOS, NR1H3 encoding for LXR α , and LXR α target genes in human HCC cell lines using the Broad Institute Cancer Cell Line Encyclopedia. (B) Relative mRNA expression of c-FOS and LXR α target genes in the indicated human HCC cell lines compared with HepG2. Bar graphs represent mean \pm SD. (C) Correlation analyses of c-FOS and LXR α target genes in the HCC-HB subtype. (D) Correlation analyses of NR1H3 encoding for LXR α , LXR α target genes, and c-FOS in human primary hepatocytes from four adult donors treated with the PPAR γ agonist rosiglitazone (ROSI) or vehicle (DMSO) for 24 h. Original data were deposited by Rogue et al. (2011) in the GEO databank under accession no. GSE27183. (E) Relative mRNA expression of LXR α and its target genes in HepG2 cells 24 h after treatment with the PPAR γ agonist pioglitazone or vehicle (DMSO). Bar graphs represent mean \pm SD; $n = 3$; DMSO-treated cells set to 1. *, $P \leq 0.05$; **, $P \leq 0.01$; by Student's t test. (F) Schematic view of c-Fos functions in liver pathology: hepatocyte-specific c-Fos expression induced in 3-wk-old mice causes metabolic changes as early as 1 mo later, manifested by inhibition of Lxr α expression and LXR/RXR pathway activity, leading to liver damage visible by localized necrotic foci. Over time, these changes, together with inflammation, induce hepatocyte proliferation, dedifferentiation, and a premalignant phenotype. Within 4 mo of c-Fos expression, hepatic cholesterol, oxysterols, and BAs accumulate, which are likely responsible together with liver dysfunction for the death of the mutant mice. When c-Fos expression is combined in adults with a single dose of DEN treatment (GOF), HCCs develop 7 mo later; in contrast, the absence of c-Fos (LOF) prevents DEN-induced HCC development when the mutagen is applied at 2 wk of age.

and free cholesterol and oxysterols. Oxysterols are LXR α natural ligands; thus, decreased LXR α activity is not caused by reduced ligand availability, but rather reduced LXR α mRNA and protein. Increased PPAR γ in *c-Fos*-expressing hepatocytes likely contributes to decreased LXR α -RXR pathway activity, possibly through direct regulation of LXR α expression. Because RXR is required as an obligatory heterodimerization partner, competitive reduction of LXR/RXR dimers by PPAR γ and FXR might also occur (Yoshikawa et al., 2003; Chan and Wells, 2009). Although systemic PPAR γ activation is considered rather beneficial in HCC (Yu et al., 2010; Wu et al., 2012), ectopic expression of PPAR γ in wild-type livers by adenoviral delivery enhances hepatocyte proliferation, increases liver size, and is deleterious in the context of Pten and Akt inactivation (Panasyuk et al., 2012). Defining the contribution of nuclear receptors such as PPAR γ , RXR, and FXR in HCC downstream or independently of AP-1 certainly merits further investigation.

The *c-Fos*-dependent metabolic alterations are similar to those observed in Lxr α knockout mice (Peet et al., 1998; Zhang and Friedman, 2012). Lxr α mutants fed a high-cholesterol diet displayed further increased hepatic cholesterol and liver dysfunction, although no malignant transformation was reported. This is surprising because an anti-oncogenic function for LXR α in cancer cell lines has been documented (Mehrotra et al., 2011; Lo Sasso et al., 2013). Consistent with our observations in *c-Fos*-expressing livers, LXR α promoted the differentiation of human liver progenitor cells (Chen et al., 2014). In a subset of human HCC tissue samples in which oxysterols and cholesterol were elevated, LXR α mRNA and LXR target gene expression were found to be significantly reduced (Lu et al., 2013). This uncoupling between LXR activity and oxysterol accumulation, which is also apparent in the livers of *c-fos*^{hep-tetOFF} mice, was attributed to impaired sterol catabolism and efflux pathways, a metabolic adaptation of tumor cells to oxysterol-induced cytotoxicity (Lu et al., 2013). Consistently, we computed an inverse correlation between *c-Fos* and LXR α target genes in human HCC cell lines and in the HCC-HB subtype, indicating that our findings in mouse models are likely relevant to human HCC.

Cholesterol is essential for proliferating cells, but an overload of intracellular cholesterol, in diseases such as atherosclerosis and Niemann-Pick type C, is cytotoxic and affects plasma membrane, ER, lysosomes, and mitochondria (Tabas, 2002; Feng et al., 2003; Ikonen, 2006; Ibrahim et al., 2011). Cholesterol derivatives such as oxysterols and BAs are hepatotoxic, genotoxic, pro-oxidative, proinflammatory, and carcinogenic (Perez and Briz, 2009; Jusakul et al., 2011; Wang et al., 2013). Oxysterols and primary BAs are increased in *c-Fos*-expressing livers, whereas BA conjugation, which results in less toxic BA species (Perez and Briz, 2009), is decreased, and mRNA expression of the two enzymes catalyzing amino acid conjugation to BA is reduced. It is thus tempting to speculate that *c-Fos*/AP-1 might modulate the expression of enzymes

implicated in BA conjugation and/or detoxification, similar to the other AP-1 protein Fra-1 (Hasenfuss et al., 2014a).

Accumulation of oxysterol and BAs, DDR, and liver damage combined with hepatic inflammation was evident in livers of *c-fos*^{hep-tetOFF} mice. Short-term treatment with atorvastatin largely prevented the deleterious consequences of *c-Fos* expression, in particular DDR activation and the early signs of preneoplastic transformation. Although long-term statin treatment of *c-fos* mutant mice might provide additional insights, these data strongly support our hypothesis, that deregulation of cholesterol metabolism caused by the LXR α -Abcg5/8 sterol transporter axis is crucial in the adverse sequence of events after increased *c-Fos* expression in hepatocytes. Preclinical and observational studies indicate that statins, widely used to treat hypercholesterolemia, might reduce HCC risk in humans (Björkhem-Bergman et al., 2014; Singh et al., 2014; Kim et al., 2017) and obese mice (Shimizu et al., 2011).

Inflammation is an important pathophysiological mechanism for HCC (Fattovich et al., 2004). Expression of *c-Fos* in hepatocytes causes liver inflammation, with granulocytes forming the bulk of recruited immune cells. The main trigger is likely the chronic damage to hepatocytes caused by accumulation of cholesterol, oxysterols, and primary BAs. Consistently, statin treatment decreased inflammatory infiltrates in the liver of *c-fos*^{hep-tetOFF} mice, whereas reducing hepatic inflammation using sulindac only modestly affected circulating cholesterol and LXR target gene expression and had little impact on DDR. In hepatocytes, inflammatory stress was reported to affect PPAR/LXR-controlled intracellular cholesterol homeostasis (Chen et al., 2012). We have documented that specific AP-1 dimers control the transcription of the nuclear receptor PPAR γ during nutrient overload (Hasenfuss et al., 2014b). Here we show that *c-Fos*/AP-1 links modulation of LXR α nuclear receptor activity to inflammatory stress (Fig. 10 F). Under stress conditions, e.g., liver regeneration, these metabolic alterations might be necessary for hepatocyte proliferation. However, chronic liver damage, inflammation, and premalignant hepatocyte transformation predispose to HCC development. Interrupting this vicious cycle of chronic inflammation, metabolic alterations, and liver damage may constitute a novel targetable pathway for HCC prevention and treatment.

MATERIALS AND METHODS

Animal procedures

The Col1a1::TetOP-*c-fos*, *LAP-tTA*, *c-fos* floxed, and *Alfp-Cre* alleles are described elsewhere (Kistner et al., 1996; Kellendonk et al., 2000; Fleischmann et al., 2003; Briso et al., 2013). *c-fos*^{hep-tetOFF} and *c-fos*^{Ali} mice were maintained on a C57BL/6 and mixed (C57BL/6 \times 129sv) background, respectively, and housed in a specific pathogen-free facility accredited by the American Association for Laboratory Animal Care, with food and water ad libitum. Doxycycline (1 g/liter) was supplied in the drinking water (Sigma-Aldrich) or in food pellets (Research Diet). Mice were treated ad libitum with sulindac (Sigma-Aldrich) supplied in the drinking water

(180 mg/L). Atorvastatin (TCI Chemicals) was dissolved at a final concentration of 20 mg/ml in cyclodextrin (5 mg/ml; Abmole Bioscience), and mice received daily oral gavage for 2 wk (100 mg/kg/d). 2-wk-old pups or 8-wk-old mice were injected intraperitoneally with 25 or 100 mg/kg DEN (Sigma-Aldrich), respectively. Mice were sacrificed 8 mo after DEN injection to monitor HCC development or earlier to analyze the acute effects of DEN. BrdU (Sigma-Aldrich) was supplied in sucrose-containing (1%) drinking water at a concentration of 1 mg/ml. Liver tumor detection by micro-computed tomography (micro-CT) was performed on anesthetized mice after intravenous injection of the iodinated contrast agent Iopamiro 300 (Bracco) using a small-animal micro-CT system (eXplore Vista PET/CT; GE Healthcare). In all experiments, sex-matched littermates were used as controls. All animal experiments were performed in accordance with institutional, national, and European guidelines for animals used in biomedical research and approved by the Spanish National Cancer Research Centre (CNIO) Institutional Animal Care and Use Committee and the CNIO-Instituto de Salud Carlos III Ethics Committee for Research and Animal Welfare.

Blood analyses

Blood was collected by submandibular vein or cardiac (experimental endpoint) puncture. Complete blood count was performed using a hematology analyzer Abacus JunVet (Diatron), and serum parameters were measured using a VetScan chemistry analyzer (Abaxis) or a Reflovet Plus blood chemistry analyzer (Scil Diagnostics) according to the manufacturer's instructions. LDL cholesterol was calculated from total cholesterol, high-density lipoprotein cholesterol, and TGs using the Friedewald formula.

Detection of DNA adducts

10 µg liver DNA was treated with 0.4 M NaOH/10 mM EDTA for 10 min at 99°C. Afterward, DNA was dot-blotted on nylon membrane with 0.4 M NaOH. Membrane was rinsed in 2× SSC buffer and air-dried. Membrane was blocked with 5% skim milk powder in 1× TBS and 0.5% Tween. For detection of DNA adducts, membrane was incubated overnight with mAb to O⁶-ethyl-2-deoxyguanosine (EM 21; Squarix). The blots were incubated with anti-mouse secondary HRP-coupled antibodies (GE Healthcare) and developed using Luminata Western HRP Substrate (EMD Millipore) and Amersham ECL Hyperfilms (GE Healthcare). Loading control was performed using methylene blue staining.

Histology and immunohistochemistry

Tissue was fixed in 4% PFA and embedded in either paraffin or OCT. Hematoxylin and eosin (H&E) staining was performed according to standard procedures. For paraffin-embedded sections, antigen retrieval was performed using citrate buffer, pH 6.0, in a pressure cooker. PBS supplemented with 0.1% Triton X-100, 0.05% Tween, and 1.5% BSA and 10% serum compatible with the secondary antibody was used

for antibody dilution. The following antibodies were used for IHC: Flag (Cell Signaling Technology), AFP (R&D Systems), CK19 (Developmental Studies Hybridoma Bank), MPO (Dako), Sox9 (Abcam), Phospho-Ser139-Histone H2AX (EMD Millipore), p53 (CNIO mAb unit), p21 (CNIO mAb unit), β-catenin (Cell Signaling Technology), CD45 (BD), Ki67 (Master Diagnostic), BrdU (AbD Serotec), GS (Sigma-Aldrich), and cleaved caspase 3 (Cell Signaling Technology) together with matching secondary antibodies from the Vectastain Elite ABC kits (Vector Laboratories). Counterstaining was performed using Carazzi's hematoxylin (Panreac Appli-Chem). Quantification was performed on digital scans using Panoramic Viewer software (3DHISTECH).

Flow cytometry

Immune cells were isolated from the liver using two-step collagenase perfusion with liver perfusion medium (Gibco) and liver digest medium (Gibco) and filtered through a 100-µm cell strainer. Hepatocytes were removed by centrifugation at 50 g. After lysing red blood cells (Sigma-Aldrich), cells were incubated with FC-Block (BD) and the following antibodies against immune cell surface markers: F4/80-AF647, CD45-PerCP, and CD45R-APC-Cy7 (BioLegend); CD3-AF700 (eBioscience); and CD4-PE-Cy7, CD8-PE-Cy5, NK1.1-PE, and Ly-6G/Ly-6C-PerCP-Cy5.5 (BD). Cells were fixed in 2% PFA. Data were acquired on a BD LSR II Fortessa and analyzed using FlowJo 9.5.3. Live cells were gated for CD45⁺, and at least 10,000 individual cells were collected. The different immune cell populations in the CD45⁺ population were gated as follows: T cells, CD3⁺, NK1.1⁻; NK cells, CD3⁻, NK1.1⁺; NKT cells, CD3⁺, NK1.1⁺; CD4⁺T cells, CD4⁺, CD8⁻; CD8⁺T cells, CD4⁻, CD8⁺; macrophages and monocytes, F4/80⁺; B cells, CD45R⁺ (B220⁺); and granulocytes, Gr1⁺ (Ly-6G/Ly-6C).

Protein isolation and Western blot

Tissue was disrupted using a Precellys device (Bertin Technologies) in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, and 0.1% SDS). Protein lysates were quantified using BCA protein assay reagent (Thermo Fisher Scientific). For Western blot analysis, 50 µg protein per sample was loaded. Membranes were blocked with 5% BSA or nonfat dry milk in TBS-T. The following primary antibodies were used: c-Fos (Santa Cruz Biotechnology, Inc.), p-AKT (Cell Signaling Technology), AKT (Cell Signaling Technology), p-Stat3 (Cell Signaling Technology), Stat3 (Cell Signaling Technology), p-JNK (Cell Signaling Technology), JNK (Cell Signaling Technology), Vinculin (Sigma-Aldrich), LXRA (R&D Systems), Srebf1 (Abcam), Srebf2 (Abcam), and Gapdh (Sigma-Aldrich). Blots were incubated with the appropriate secondary HRP-coupled antibody (GE Healthcare and Santa Cruz Biotechnology, Inc.) and developed using Luminata Western HRP Substrate (EMD Millipore) and Amersham ECL Hyperfilms (GE Healthcare) or a ChemiDoc XRS+ imaging system with Image Lab image acquisition and analysis software (Bio-Rad).

Cell culture

Primary mouse hepatocytes were isolated from adult mice and cultivated as previously described (Hasenfuss et al., 2014a), and doxycycline (Sigma-Aldrich) was dissolved in water and added to reach a final concentration of 1 µg/ml. Human HepG2, Huh7, and SNU354 cellular carcinoma cell lines were maintained in DMEM supplemented with 10% FBS. A final concentration of 50 µM of the PPAR γ agonist pioglitazone (Sigma-Aldrich; dissolved in DMSO) was used to treat HepG2 cells during 24 h without obvious effect on cell viability.

RNA isolation and RT-PCR

Total RNA was isolated using TRI Reagent (Sigma-Aldrich), complementary DNA was synthesized using Ready-To-Go-You-Prime-First-Strand Beads (GE Healthcare), and RT-qPCR used GoTaq RT-qPCR Master Mix (Promega) and Eppendorf fluorescence thermocyclers, all according to manufacturers' instructions. The $2^{-\Delta\Delta CT}$ method was used to quantify amplified fragments. Expression levels were normalized using at least one housekeeping gene (*gapdh* and *actin*). Primer sequences are listed in Table S2.

RNA-seq and data analysis

Total RNA was isolated using TRI Reagent (Sigma-Aldrich), and RNA integrity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies). Samples of RNA integrity score >8 were used for RNA-seq. RNA processing was performed as described in Illumina's TruSeq RNA Sample Preparation V2 (Part #15026495 Rev B, February 2012). The resulting purified cDNA library was applied to an Illumina flow cell for cluster generation (TruSeq cluster generation kit v5) and sequenced on the Genome Analyzer IIx with SBS TruSeq v5 reagents according to the manufacturer's protocols. RNA-seq read quality was checked with FastQC (Andrews, 2010). Fastq files (Cock et al., 2010) were randomly down-sampled to generate datasets with similar numbers of reads in all the samples.

The 40-nt single-end reads were aligned to the mouse genome (GRCm38/mm10) with TopHat-2.0.4 (Trapnell et al., 2012), using Bowtie 0.12.7 (Langmead et al., 2009) and Samtools 0.1.16 (Li et al., 2009), allowing two mismatches and five multihits. Transcript assembly and estimation of abundance were calculated with Cufflinks 1.3.0, using the mouse genome annotation dataset GRCm38/mm10 from the UCSC Genome Browser (Karolchik et al., 2014). Differential expression between genes in both conditions was calculated with Cuffdiff (Trapnell et al., 2012), and those genes with FPKM expression values lower than 0.05 in both conditions were excluded. GSEA was performed to test for relevant pathways in the data (Subramanian et al., 2005). Data are deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession no. GSE81079.

Metabolite measurements

Liver samples were homogenized using chloroform/isopropanol/NP-40 (7:11:0.1). Chloroform was removed from

the supernatant by vacuum centrifugation (GeneVac). Colorimetric cholesterol was measured using a BioVision kit (K603-100). NMR was performed at the Spectroscopy and Nuclear Magnetic Resonance Spectroscopy Unit. Oxysterols and BAs were measured by Biocrates Life Sciences AG (Innsbruck, Austria) using mass spectrometry. The sum of all oxysterols species resolved by liquid chromatography/tandem mass spectrometry (LC-MS/MS) as well as individual species was analyzed.

For determination of liver metabolite concentrations by NMR (Beckonert et al., 2007), dual-phase fractionation using extraction in methanol/water/chloroform (1:1:1) was used, according to a modified Salomon protocol for the simultaneous extraction of polar and apolar metabolites (Tyagi et al., 1996). In brief, 150–200 mg of tissue samples were disrupted in a Precellys 24 device using 3 ml of ice-cold methanol and transferred to centrifuge glass tubes (30-ml borosilicate glass tubes; Kimble-Chase), where equal volumes of methanol and water were sequentially added and vigorously mixed. Fractionation was accelerated by centrifugation at 5,000 g for 15 min at 4°C, after which the polar and apolar fractions were carefully separated and the latter dried by vacuum centrifugation (GeneVac). NMR samples of the apolar fractions were prepared by dissolving the dry extract in 500 µl of DCCl₃ plus 300 µl of 20 mM deuterated EDTA, pH 6.0, in D₂O/deuterated methanol (1:2) and transferred to 5-mm NMR tubes for measurement. High-resolution NMR spectra were registered on a Bruker Avance spectrometer operating at 16.4 T (proton Larmor frequency of 700 MHz) at 293 K using a TXI probe with pulsed field gradient capabilities and equipped with a BACS120 sample changer. 1D proton NMR spectra (1dH) of the apolar fraction of the liver lysates were recorded using a NOESY pulse sequence (noesygp1d in Bruker nomenclature) using pulse field gradients during the mixing time of 10 ms and a 2-s recovery delay between consecutive scans. 256 scans were accumulated using a spectral width of 20 ppm centered at 6.37 ppm and with acquisition time of 1.6 s, resulting in an acquisition time of 16.5 min per sample. In addition, 2D sensitivity-enhanced ¹H-¹³C heteronuclear single quantum coherence spectra (2dHC, hsqcqtgpcisp2 in Bruker nomenclature; Schleucher et al., 1994) were recorded for each apolar extract sample (¹³C natural abundance) with ¹³C decoupling during the 60-ms acquisition time, using an indirect (¹³C) spectral width of 40 ppm centered at 68 ppm, with 35 indirect increments (complex points), 256 scans per increment, and 1.2-s recovery delay, resulting in a total acquisition time of 6.5 h per 2dHC spectrum. All 1dH free induction decays were processed with exponential multiplication (0.5 Hz line-broadening) before Fourier transformation and followed by baseline correction using Topspin2.1 (Bruker). The 2dHC spectra were processed with NMRPipe (Delaglio et al., 1995) using squared cosine window functions in both dimensions, and were visualized and analyzed using nmrViewJ (Johnson, 2004). ¹H/¹³C chemical shifts were referenced to internal deuterated methanol (3.36/49.6 ppm). Metabolites in 1dH spectra

were quantified from their signal/s integral/s, using integration regions of variable size that were manually defined to include all metabolite signals using AMIX3.8 software (Bruker). The relative levels of cholesterol and lipids were obtained from the maximum intensity of the most intense and best-resolved correlations (or combinations thereof) of the different chemical moieties for each metabolite (Vinaixa et al., 2010), as detected in the 2dHC spectra. For example, for assessing total cholesterol, the mean of four NMR signals corresponding to five methyl groups (C18, C19, C21, and C26 and C27, which overlap) was used. Reported metabolite concentrations are normalized to total extracted metabolites, as calculated from the relative sum of all metabolite signals in 1dH spectra, and thus accounting for metabolite level differences resulting from different mass of liver tissue and possible differences in extraction efficiency as described in Petruzzelli et al. (2014).

To extract metabolites from liver tissue for mass spectrometry, samples were homogenized using Precellys with 100% ethanol containing 0.01% butylated hydroxytoluene. For measuring metabolite concentrations, samples were centrifuged, and the supernatant was used for analysis. Biocrates Bile Acids kit validated for mouse plasma was used for BA quantification. A highly selective reversed-phase LC-MS/MS analysis method in negative ion multiple reaction monitoring (MRM) detection mode was applied to determine the concentrations of BAs. Samples were extracted via dried filter spot technique in 96-well plate format. Sample extracts were measured by electrospray ionization LC-MS/MS (SCIEX, Thermo Fisher Scientific, or Waters Corp.). For highly accurate quantification, seven-point external calibration curves and 10 stable isotope-labeled internal standards were applied. Data of BAs were quantified using the appropriate MS software (SCIEX, Analyst; Thermo Fisher Scientific, Xcalibur; and Waters, MassLynx), and the results were imported into Biocrates MetIDQ software for further analysis. Oxysterols, both free and esterified, were extracted from samples with methanol using a Biocrates kit filter plate. The plate was loaded with an internal standard mixture beforehand. The extract was then subjected to alkaline hydrolysis to release oxysterols from their respective esters. After neutralization, the metabolites were determined by ultra-high-performance LC-MS/MS with MRM in positive mode using a SCIEX API Qtrap 5500 mass spectrometer with electrospray ionization. The assay has been validated according to European Medicines Agency guidelines.

Statistics

Data are expressed as mean \pm SD. Statistical significance was determined using two-tailed Student's *t* test for all bar graphs and two-way ANOVA for all plots, except for Kaplan–Meier plots where Mantel–Cox log-rank was used. For all experiments, values of $P < 0.05$ were considered statistically significant.

Online supplemental material

Fig. S1 shows additional phenotypic consequences of hepatocyte-specific *c-Fos* expression. Fig. S2 shows DEN experi-

ments using *c-Fos* loss- and gain-of-function mutant mice. Fig. S3 includes additional early DEN-induced events in *c-Fos* mutants and illustrates the reversibility of the *c-Fos*-induced phenotype. Fig. S4 shows additional liver metabolic pathways affected by *c-Fos*. Fig. S5 depicts data supporting the *c-Fos*–LXR α connection in mouse and human samples. Table S1 lists the full and abbreviated name of BAs and oxysterols species determined by mass spectrometry. Table S2 lists the specific primers used in this study.

ACKNOWLEDGMENTS

We thank Drs. N. Djouder, M. Petruzzelli, R. Ricci, F.X. Real, K.D. Bissig, and members of the Wagner laboratory for critical reading of the manuscript and valuable suggestions; Dr. H. Schönthaler for help with the bioinformatics analysis; V. Berneo for technical help; and G. Luque, S. Leceta, and G. Medrano for assisting with mouse experiments.

The E.F. Wagner laboratory is supported by grants from the Spanish Ministry of Economy, Industry, and Competitiveness (BFU2012-40230 and SAF2015-70857, co-funded by the European Regional Development Fund), a European Research Council-advanced grant (ERC-FCK/2008/37), and Worldwide Cancer Research (13-0216). R. Hamacher was supported by the Deutsche Forschungsgemeinschaft (HA 6068/1-1), M.K. Thomsen by AUFF Nova, and S.C. Hasenfuss by a Boehringer Ingelheim Fonds PhD fellowship.

The authors declare no competing financial interests.

Author contributions: L. Bakiri and R. Hamacher designed and performed experiments, analyzed data, prepared figures, and wrote the manuscript. O. Graña analyzed RNA-seq and public microarray data, A. Guío-Carrión provided expert technical assistance, R. Campos-Olivas acquired and analyzed NMR data, L. Martínez analyzed flow cytometry data, M.K. Thomsen performed experiments with human cell lines, S.C. Hasenfuss performed experiments with primary hepatocytes and data mining, and H.P. Dienes performed pathological analysis on tissue sections. E.F. Wagner directed the study, approved the data, and wrote and edited the paper. All authors read and commented on the manuscript.

Submitted: 20 June 2016

Revised: 12 December 2016

Accepted: 7 February 2017

REFERENCES

- Andrews, S. 2010. FastQC a quality control tool for high throughput sequence data. Available at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc> (accessed March 1, 2013)
- Bakiri, L., and E.F. Wagner. 2013. Mouse models for liver cancer. *Mol. Oncol.* 7:206–223. <http://dx.doi.org/10.1016/j.molonc.2013.01.005>
- Beckonert, O., H.C. Keun, T.M. Ebbels, J. Bundy, E. Holmes, J.C. Lindon, and J.K. Nicholson. 2007. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat. Protoc.* 2:2692–2703. <http://dx.doi.org/10.1038/nprot.2007.376>
- Björkhem-Bergman, L., M. Backheden, and K. Söderberg Löfdal. 2014. Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer—results from a nationwide case-control study in Sweden. *Pharmacoepidemiol. Drug Saf.* 23:1101–1106. <http://dx.doi.org/10.1002/pds.3685>
- Boyault, S., D.S. Rickman, A. de Reyniès, C. Balabaud, S. Rebouissou, E. Jeannot, A. Hérault, J. Saric, J. Belghiti, D. Franco, et al. 2007. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. *Hepatology.* 45:42–52. <http://dx.doi.org/10.1002/hep.21467>

- Briso, E.M., J. Guinea-Viniegra, L. Bakiri, Z. Rogon, P. Petzelbauer, R. Eils, R. Wolf, M. Rincón, P. Angel, and E.F. Wagner. 2013. Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos. *Genes Dev.* 27:1959–1973. <http://dx.doi.org/10.1101/gad.223339.113>
- Cairo, S., C. Armengol, A. De Reyniès, Y. Wei, E. Thomas, C.A. Renard, A. Goga, A. Balakrishnan, M. Semeraro, L. Gresh, et al. 2008. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. *Cancer Cell.* 14:471–484. <http://dx.doi.org/10.1016/j.ccr.2008.11.002>
- Calkin, A.C., and P. Tontonoz. 2012. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. *Nat. Rev. Mol. Cell Biol.* 13:213–224. <http://dx.doi.org/10.1038/nrm3312>
- Chan, L.S., and R.A. Wells. 2009. Cross-talk between PPARs and the partners of RXR: A molecular perspective. *PPAR Res.* 2009:925309. <http://dx.doi.org/10.1155/2009/925309>
- Chen, K.T., K. Pernelle, Y.H. Tsai, Y.H. Wu, J.Y. Hsieh, K.H. Liao, C. Guguen-Guillouzo, and H.W. Wang. 2014. Liver X receptor α (LXR α /NR1H3) regulates differentiation of hepatocyte-like cells via reciprocal regulation of HNF4 α . *J. Hepatol.* 61:1276–1286. <http://dx.doi.org/10.1016/j.jhep.2014.07.025>
- Chen, Y., Y. Chen, L. Zhao, Y. Chen, M. Mei, Q. Li, A. Huang, Z. Varghese, J.F. Moorhead, and X.Z. Ruan. 2012. Inflammatory stress exacerbates hepatic cholesterol accumulation via disrupting cellular cholesterol export. *J. Gastroenterol. Hepatol.* 27:974–984. <http://dx.doi.org/10.1111/j.1440-1746.2011.06986.x>
- Chiang, D.Y., A. Villanueva, Y. Hoshida, J. Peix, P. Newell, B. Minguéz, A.C. LeBlanc, D.J. Donovan, S.N. Thung, M. Solé, et al. 2008. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. *Cancer Res.* 68:6779–6788. <http://dx.doi.org/10.1158/0008-5472.CAN-08-0742>
- Chinetti, G., S. Lestavel, V. Bocher, A.T. Remaley, B. Neve, I.P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, et al. 2001. PPAR- α and PPAR- γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nat. Med.* 7:53–58. <http://dx.doi.org/10.1038/83348>
- Cock, P.J., C.J. Fields, N. Goto, M.L. Heuer, and P.M. Rice. 2010. The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants. *Nucleic Acids Res.* 38:1767–1771. <http://dx.doi.org/10.1093/nar/gkp1137>
- Degirrolamo, C., S. Modica, M. Vacca, G. Di Tullio, A. Morgano, A. D’Orazio, K. Kannisto, P. Parini, and A. Moschetta. 2015. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. *Hepatology.* 61:161–170. <http://dx.doi.org/10.1002/hep.27274>
- Delaglio, F., S. Grzesiek, G.W. Vuister, G. Zhu, J. Pfeifer, and A. Bax. 1995. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR.* 6:277–293. <http://dx.doi.org/10.1007/BF00197809>
- Eferl, R., and E.F. Wagner. 2003. AP-1: A double-edged sword in tumorigenesis. *Nat. Rev. Cancer.* 3:859–868. <http://dx.doi.org/10.1038/nrc1209>
- Eferl, R., R. Ricci, L. Kenner, R. Zenz, J.P. David, M. Rath, and E.F. Wagner. 2003. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. *Cell.* 112:181–192. [http://dx.doi.org/10.1016/S0092-8674\(03\)00042-4](http://dx.doi.org/10.1016/S0092-8674(03)00042-4)
- Fan, Q., M. He, X. Deng, W.K. Wu, L. Zhao, J. Tang, G. Wen, X. Sun, and Y. Liu. 2013. Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. *Cell Biochem. Funct.* 31:319–324. <http://dx.doi.org/10.1002/cbf.2902>
- Farazi, P.A., and R.A. DePinho. 2006. Hepatocellular carcinoma pathogenesis: From genes to environment. *Nat. Rev. Cancer.* 6:674–687. <http://dx.doi.org/10.1038/nrc1934>
- Fattovich, G., T. Stroffolini, I. Zagni, and F. Donato. 2004. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. *Gastroenterology.* 127:S35–S50. <http://dx.doi.org/10.1053/j.gastro.2004.09.014>
- Feng, B., P.M. Yao, Y. Li, C.M. Devlin, D. Zhang, H.P. Harding, M. Sweeney, J.X. Rong, G. Kuriakose, E.A. Fisher, et al. 2003. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. *Nat. Cell Biol.* 5:781–792. <http://dx.doi.org/10.1038/ncb1035>
- Fleischmann, A., O. Hvalby, V. Jensen, T. Strekalova, C. Zacher, L.E. Layer, A. Kvello, M. Reschke, R. Spanagel, R. Sprengel, et al. 2003. Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. *J. Neurosci.* 23:9116–9122.
- Fu, Z.D., J.Y. Cui, and C.D. Klaassen. 2014. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice. *J. Lipid Res.* 55:2576–2586. <http://dx.doi.org/10.1194/jlr.M053124>
- Fuest, M., K. Willim, S. MacNelly, N. Fellner, G.P. Resch, H.E. Blum, and P. Hasselblatt. 2012. The transcription factor c-Jun protects against sustained hepatic endoplasmic reticulum stress thereby promoting hepatocyte survival. *Hepatology.* 55:408–418. <http://dx.doi.org/10.1002/hep.24699>
- Güller, M., K. Toualbi-Abed, A. Legrand, L. Michel, A. Mauviel, D. Bernuau, and F. Daniel. 2008. c-Fos overexpression increases the proliferation of human hepatocytes by stabilizing nuclear Cyclin D1. *World J. Gastroenterol.* 14:6339–6346. <http://dx.doi.org/10.3748/wjg.14.6339>
- Hasenfuss, S.C., L. Bakiri, M.K. Thomsen, R. Hamacher, and E.F. Wagner. 2014a. Activator Protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. *Hepatology.* 59:261–273. <http://dx.doi.org/10.1002/hep.26518>
- Hasenfuss, S.C., L. Bakiri, M.K. Thomsen, E.G. Williams, J. Auwerx, and E.F. Wagner. 2014b. Regulation of steatohepatitis and PPAR γ signaling by distinct AP-1 dimers. *Cell Metab.* 19:84–95. <http://dx.doi.org/10.1016/j.cmet.2013.11.018>
- Hasselblatt, P., M. Rath, V. Komnenovic, K. Zatloukal, and E.F. Wagner. 2007. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. *Proc. Natl. Acad. Sci. USA.* 104:17105–17110. <http://dx.doi.org/10.1073/pnas.0706272104>
- He, G., and M. Karin. 2011. NF- κ B and STAT3 – key players in liver inflammation and cancer. *Cell Res.* 21:159–168. <http://dx.doi.org/10.1038/cr.2010.183>
- Holzbaumer, A., V.M. Factor, J.B. Andersen, J.U. Marquardt, D.E. Kleiner, C. Raggi, M. Kitade, D. Seo, H. Akita, M.E. Durkin, and S.S. Thorgeirsson. 2013. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. *Gastroenterology.* 145:221–231. <http://dx.doi.org/10.1053/j.gastro.2013.03.013>
- Horton, J.D., N.A. Shah, J.A. Warrington, N.N. Anderson, S.W. Park, M.S. Brown, and J.L. Goldstein. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. *Proc. Natl. Acad. Sci. USA.* 100:12027–12032. <http://dx.doi.org/10.1073/pnas.1534923100>
- Hoshida, Y., S.M. Nijman, M. Kobayashi, J.A. Chan, J.P. Brunet, D.Y. Chiang, A. Villanueva, P. Newell, K. Ikeda, M. Hashimoto, et al. 2009. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Res.* 69:7385–7392. <http://dx.doi.org/10.1158/0008-5472.CAN-09-1089>
- Hoshida, Y., S. Toffanin, A. Lachenmayer, A. Villanueva, B. Minguéz, and J.M. Llovet. 2010. Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements. *Semin. Liver Dis.* 30:035–051. <http://dx.doi.org/10.1055/s-0030-1247131>
- Hsiao, L.L., F. Dangond, T. Yoshida, R. Hong, R.V. Jensen, J. Misra, W. Dillon, K.F. Lee, K.E. Clark, P. Haverty, et al. 2001. A compendium of gene expression in normal human tissues. *Physiol. Genomics.* 7:97–104. <http://dx.doi.org/10.1152/physiolgenomics.00040.2001>

- Hui, L., L. Bakiri, A. Mairhorfer, N. Schweifer, C. Haslinger, L. Kenner, V. Komnenovic, H. Scheuch, H. Beug, and E.F. Wagner. 2007. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. *Nat. Genet.* 39:741–749. <http://dx.doi.org/10.1038/ng2033>
- Ibrahim, S.H., R. Kohli, and G.J. Gores. 2011. Mechanisms of lipotoxicity in NAFLD and clinical implications. *J. Pediatr. Gastroenterol. Nutr.* 53:131–140. <http://dx.doi.org/10.1097/MPG.0b013e31822578db>
- Ikonen, E. 2006. Mechanisms for cellular cholesterol transport: Defects and human disease. *Physiol. Rev.* 86:1237–1261. <http://dx.doi.org/10.1152/physrev.00022.2005>
- Jain, S., S. Singhal, P. Lee, and R. Xu. 2010. Molecular genetics of hepatocellular neoplasia. *Am. J. Transl. Res.* 2:105–118.
- Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. *CA Cancer J. Clin.* 61:69–90. <http://dx.doi.org/10.3322/caac.20107>
- Johnson, B.A. 2004. Using NMRView to visualize and analyze the NMR spectra of macromolecules. *Methods Mol. Biol.* 278:313–352.
- Jusakul, A., P. Yongvanit, W. Loilome, N. Namwat, and R. Kuver. 2011. Mechanisms of oxysterol-induced carcinogenesis. *Lipids Health Dis.* 10:44. <http://dx.doi.org/10.1186/1476-511X-10-44>
- Karolchik, D., G.P. Barber, J. Casper, H. Clawson, M.S. Cline, M. Diekhans, T.R. Dreszer, P.A. Fujita, L. Guruvadoo, M. Haussler, et al. 2014. The UCSC Genome Browser database: 2014 update. *Nucleic Acids Res.* 42:D764–D770. <http://dx.doi.org/10.1093/nar/gkt1168>
- Kellendonk, C., C. Opherck, K. Anlag, G. Schütz, and F. Tronche. 2000. Hepatocyte-specific expression of Cre recombinase. *Genesis.* 26:151–153. [http://dx.doi.org/10.1002/\(SICI\)1526-968X\(200002\)26:2<151::AID-GENE17>3.0.CO;2-E](http://dx.doi.org/10.1002/(SICI)1526-968X(200002)26:2<151::AID-GENE17>3.0.CO;2-E)
- Kim, G., S.Y. Jang, E. Han, Y.H. Lee, S.Y. Park, C.M. Nam, and E.S. Kang. 2017. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. *Int. J. Cancer.* 140:798–806. <http://dx.doi.org/10.1002/ijc.30506>
- Kim, I., K. Morimura, Y. Shah, Q. Yang, J.M. Ward, and F.J. Gonzalez. 2007. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. *Carcinogenesis.* 28:940–946. <http://dx.doi.org/10.1093/carcin/bgl249>
- Kinner, A., W. Wu, C. Staudt, and G. Iliakis. 2008. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. *Nucleic Acids Res.* 36:5678–5694. <http://dx.doi.org/10.1093/nar/gkn550>
- Kistner, A., M. Gossen, F. Zimmermann, J. Jerecic, C. Ullmer, H. Lübbert, and H. Bujard. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. *Proc. Natl. Acad. Sci. USA.* 93:10933–10938. <http://dx.doi.org/10.1073/pnas.93.20.10933>
- Laffitte, B.A., S.B. Joseph, R. Walczak, L. Pei, D.C. Wilpitz, J.L. Collins, and P. Tontonoz. 2001. Autoregulation of the human liver X receptor alpha promoter. *Mol. Cell. Biol.* 21:7558–7568. <http://dx.doi.org/10.1128/MCB.21.22.7558-7568.2001>
- Langmead, B., C. Trapnell, M. Pop, and S.L. Salzberg. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* 10:R25. <http://dx.doi.org/10.1186/gb-2009-10-3-r25>
- Lawman, S., C. Mauri, E.C. Jury, H.T. Cook, and M.R. Ehrenstein. 2004. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. *J. Immunol.* 173:7641–7646. <http://dx.doi.org/10.4049/jimmunol.173.12.7641>
- Lee, J.S., J. Heo, L. Libbrecht, I.S. Chu, P. Kaposi-Novak, D.F. Calvisi, A. Mikaelyan, L.R. Roberts, A.J. Demetris, Z. Sun, et al. 2006. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. *Nat. Med.* 12:410–416. <http://dx.doi.org/10.1038/nm1377>
- Li, H., B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, and R. Durbin. 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. *Bioinformatics.* 25:2078–2079. <http://dx.doi.org/10.1093/bioinformatics/btp352>
- Liu, P., E. Kimmoun, A. Legrand, A. Sauvanet, C. Degott, B. Lardeux, and D. Bernuau. 2002. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. *J. Hepatol.* 37:63–71. [http://dx.doi.org/10.1016/S0168-8278\(02\)00064-8](http://dx.doi.org/10.1016/S0168-8278(02)00064-8)
- Lo Sasso, G., F. Bovenga, S. Murzilli, L. Salvatore, G. Di Tullio, N. Martelli, A. D'Orazio, S. Rainaldi, M. Vacca, A. Mangia, et al. 2013. Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. *Gastroenterology.* 144:1497–1507.e13. <http://dx.doi.org/10.1053/j.gastro.2013.02.005>
- Lu, M., X.H. Hu, Q. Li, Y. Xiong, G.J. Hu, J.J. Xu, X.N. Zhao, X.X. Wei, C.C. Chang, Y.K. Liu, et al. 2013. A specific cholesterol metabolic pathway is established in a subset of HCCs for tumor growth. *J. Mol. Cell Biol.* 5:404–415. <http://dx.doi.org/10.1093/jmcb/mjt039>
- Machida, K., H. Tsukamoto, J.C. Liu, Y.P. Han, S. Govindarajan, M.M. Lai, S. Akira, and J.H. Ou. 2010. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. *Hepatology.* 52:480–492. <http://dx.doi.org/10.1002/hep.23697>
- Mehrotra, A., D. Kaul, and K. Joshi. 2011. LXR- α selectively reprogrammes cancer cells to enter into apoptosis. *Mol. Cell. Biochem.* 349:41–55. <http://dx.doi.org/10.1007/s11010-010-0659-3>
- Michelotti, G.A., M.V. Machado, and A.M. Diehl. 2013. NAFLD, NASH and liver cancer. *Nat. Rev. Gastroenterol. Hepatol.* 10:656–665. <http://dx.doi.org/10.1038/nrgastro.2013.183>
- Min, L., Y. Ji, L. Bakiri, Z. Qiu, J. Cen, X. Chen, L. Chen, H. Scheuch, H. Zheng, L. Qin, et al. 2012. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. *Nat. Cell Biol.* 14:1203–1211. <http://dx.doi.org/10.1038/ncb2590>
- Nault, J.C., and J. Zucman-Rossi. 2011. Genetics of hepatobiliary carcinogenesis. *Semin. Liver Dis.* 31:173–187. <http://dx.doi.org/10.1055/s-0031-1276646>
- Panasyuk, G., C. Espeillac, C. Chauvin, L.A. Pradelli, Y. Horie, A. Suzuki, J.S. Annicotte, L. Fajas, M. Foretz, F. Verdegue, et al. 2012. PPAR γ contributes to PKM2 and HK2 expression in fatty liver. *Nat. Commun.* 3:672. <http://dx.doi.org/10.1038/ncomms1667>
- Parker, R.A., R. Garcia, C.S. Ryan, X. Liu, P. Shipkova, V. Livanov, P. Patel, and S.P. Ho. 2013. Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. *J. Lipid Res.* 54:2400–2409. <http://dx.doi.org/10.1194/jlr.M038331>
- Peet, D.J., S.D. Turley, W. Ma, B.A. Janowski, J.M. Lobaccaro, R.E. Hammer, and D.J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. *Cell.* 93:693–704. [http://dx.doi.org/10.1016/S0092-8674\(00\)81432-4](http://dx.doi.org/10.1016/S0092-8674(00)81432-4)
- Perez, M.J., and O. Briz. 2009. Bile-acid-induced cell injury and protection. *World J. Gastroenterol.* 15:1677–1689. <http://dx.doi.org/10.3748/wjg.15.1677>
- Petruzzelli, M., M. Schweiger, R. Schreiber, R. Campos-Olivas, M. Tsoli, J. Allen, M. Swarbrick, S. Rose-John, M. Rincon, G. Robertson, et al. 2014. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. *Cell Metab.* 20:433–447. <http://dx.doi.org/10.1016/j.cmet.2014.06.011>
- Pinyol, R., J.C. Nault, I.M. Quetglas, J. Zucman-Rossi, and J.M. Llovet. 2014. Molecular profiling of liver tumors: Classification and clinical translation for decision making. *Semin. Liver Dis.* 34:363–375. <http://dx.doi.org/10.1055/s-0034-1394137>

- Rogue, A., C. Lambert, R. Jossé, S. Antherieu, C. Spire, N. Claude, and A. Guillouzo. 2011. Comparative gene expression profiles induced by PPAR γ and PPAR α/γ agonists in human hepatocytes. *PLoS One*. 6:e18816. <http://dx.doi.org/10.1371/journal.pone.0018816>
- Sakurai, T., S. Maeda, L. Chang, and M. Karin. 2006. Loss of hepatic NF- κ B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. *Proc. Natl. Acad. Sci. USA*. 103:10544–10551. <http://dx.doi.org/10.1073/pnas.0603499103>
- Schleucher, J., M. Schwendinger, M. Sattler, P. Schmidt, O. Schedletzky, S.J. Glaser, O.W. Sørensen, and C. Griesinger. 1994. A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients. *J. Biomol. NMR*. 4:301–306. <http://dx.doi.org/10.1007/BF00175254>
- Seki, E., D.A. Brenner, and M. Karin. 2012. A liver full of JNK: Signaling in regulation of cell function and disease pathogenesis, and clinical approaches. *Gastroenterology*. 143:307–320. <http://dx.doi.org/10.1053/j.gastro.2012.06.004>
- Shimizu, M., Y. Yasuda, H. Sakai, M. Kubota, D. Terakura, A. Baba, T. Ohno, T. Kochi, H. Tsurumi, T. Tanaka, and H. Moriwaki. 2011. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. *BMC Cancer*. 11:281. <http://dx.doi.org/10.1186/1471-2407-11-281>
- Singh, S., P.P. Singh, L.R. Roberts, and W. Sanchez. 2014. Chemopreventive strategies in hepatocellular carcinoma. *Nat. Rev. Gastroenterol. Hepatol.* 11:45–54. <http://dx.doi.org/10.1038/nrgastro.2013.143>
- Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA*. 102:15545–15550. <http://dx.doi.org/10.1073/pnas.0506580102>
- Tabas, I. 2002. Consequences of cellular cholesterol accumulation: Basic concepts and physiological implications. *J. Clin. Invest.* 110:905–911. <http://dx.doi.org/10.1172/JCI0216452>
- Trapnell, C., A. Roberts, L. Goff, G. Pertea, D. Kim, D.R. Kelley, H. Pimentel, S.L. Salzberg, J.L. Rinn, and L. Pachter. 2012. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat. Protoc.* 7:562–578. <http://dx.doi.org/10.1038/nprot.2012.016>
- Trierweiler, C., H.E. Blum, and P. Hasselblatt. 2012. The transcription factor c-Jun protects against liver damage following activated β -Catenin signaling. *PLoS One*. 7:e40638. <http://dx.doi.org/10.1371/journal.pone.0040638>
- Trierweiler, C., B. Hockenjos, K. Zatloukal, R. Thimme, H.E. Blum, E.F. Wagner, and P. Hasselblatt. 2016. The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. *Cell Death Differ.* 23:576–582. <http://dx.doi.org/10.1038/cdd.2015.121>
- Tyagi, R.K., A. Azrad, H. Degani, and Y. Salomon. 1996. Simultaneous extraction of cellular lipids and water-soluble metabolites: Evaluation by NMR spectroscopy. *Magn. Reson. Med.* 35:194–200. <http://dx.doi.org/10.1002/mrm.1910350210>
- van Malenstein, H., J. van Pelt, and C. Verslype. 2011. Molecular classification of hepatocellular carcinoma anno 2011. *Eur. J. Cancer*. 47:1789–1797. <http://dx.doi.org/10.1016/j.ejca.2011.04.027>
- Villanueva, A., V. Hernandez-Gea, and J.M. Llovet. 2013. Medical therapies for hepatocellular carcinoma: A critical view of the evidence. *Nat. Rev. Gastroenterol. Hepatol.* 10:34–42. <http://dx.doi.org/10.1038/nrgastro.2012.199>
- Vinaixa, M., M.A. Rodríguez, A. Rull, R. Beltrán, C. Bladé, J. Brezmes, N. Cañellas, J. Joven, and X. Correig. 2010. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. *J. Proteome Res.* 9:2527–2538. <http://dx.doi.org/10.1021/pr901203w>
- Wagner, E.F., and A.R. Nebreda. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. *Nat. Rev. Cancer*. 9:537–549. <http://dx.doi.org/10.1038/nrc2694>
- Wang, X., X. Fu, C. Van Ness, Z. Meng, X. Ma, and W. Huang. 2013. Bile acid receptors and liver cancer. *Curr. Pathobiol. Rep.* 1:29–35. <http://dx.doi.org/10.1007/s40139-012-0003-6>
- Wu, C.W., G.C. Farrell, and J. Yu. 2012. Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma. *J. Gastroenterol. Hepatol.* 27:1665–1669. <http://dx.doi.org/10.1111/j.1440-1746.2012.07213.x>
- Yang, F., X. Huang, T. Yi, Y. Yen, D.D. Moore, and W. Huang. 2007. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. *Cancer Res.* 67:863–867. <http://dx.doi.org/10.1158/0008-5472.CAN-06-1078>
- Yoshikawa, T., T. Ide, H. Shimano, N. Yahagi, M. Amemiya-Kudo, T. Matsuzaka, S. Yatoh, T. Kitamine, H. Okazaki, Y. Tamura, et al. 2003. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. *Mol. Endocrinol.* 17:1240–1254. <http://dx.doi.org/10.1210/me.2002-0190>
- Yu, J., B. Shen, E.S. Chu, N. Teoh, K.F. Cheung, C.W. Wu, S. Wang, C.N. Lam, H. Feng, J. Zhao, et al. 2010. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. *Hepatology*. 51:2008–2019. <http://dx.doi.org/10.1002/hep.23550>
- Yuen, M.F., P.C. Wu, V.C. Lai, J.Y. Lau, and C.L. Lai. 2001. Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. *Cancer*. 91:106–112. [http://dx.doi.org/10.1002/1097-0142\(20010101\)91:1<106::AID-CNCR14>3.0.CO;2-2](http://dx.doi.org/10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2)
- Zhang, D.Y., and S.L. Friedman. 2012. Fibrosis-dependent mechanisms of hepatocarcinogenesis. *Hepatology*. 56:769–775. <http://dx.doi.org/10.1002/hep.25670>
- Zhang, Y., L.W. Castellani, C.J. Sinal, F.J. Gonzalez, and P.A. Edwards. 2004. Peroxisome proliferator-activated receptor- γ coactivator 1 α (PGC-1 α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. *Genes Dev.* 18:157–169. <http://dx.doi.org/10.1101/gad.1138104>
- Zhang, Y., S.R. Breevoort, J. Angdisen, M. Fu, D.R. Schmidt, S.R. Holmstrom, S.A. Klierer, D.J. Mangelsdorf, and I.G. Schulman. 2012. Liver LXR α expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. *J. Clin. Invest.* 122:1688–1699. <http://dx.doi.org/10.1172/JCI59817>